Posted by Michael Wonder on 05 Sep 2024
Axsome Therapeutics announces FDA acceptance of NDA resubmission for AXS-07 for the acute treatment of migraine
4 September 2024 - Axsome Therapeutics today announced that the US FDA has acknowledged the resubmission of the Company’s new drug application for AXS-07 for the acute treatment of migraine.
The FDA designated the resubmission as a Class 2 resubmission and set a PDUFA action goal date of 31 January 2025.
